Analytical Data
-
Gene name
MAGEA5
- Application
-
Alternative Names
MAGEA5P;MAGE5;MAGEA5;Putative melanoma-associated antigen 5P
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43359
-
Expression Region
1-124aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSHGASAIPTAID FTLWRQSIKG SSNQEEEGPS TSPDPESVFR AALSKKVADL IHFLLLKYMSLEQK SQHCKPEEGL DTQEEALGLV GVQAATTEEQ EAVSSSSPLV PGTLGEVPAA GSPGPLKSPQ
-
Molecular Weight
16 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEA5, a member of the MAGE (Melanoma Antigen Gene) family, is a cancer/testis antigen primarily expressed in various tumors and limited normal tissues, making it an attractive target for cancer immunotherapy. Unlike many antigens, MAGEA5 is not found in normal somatic cells, which heightens its potential as a therapeutic target for tumor-specific treatments while mitigating the risk of off-target effects in healthy tissues. Research on MAGEA5 recombinant proteins has gained traction due to their potential applications in vaccine development and personalized cancer therapy. The immunogenic properties of MAGEA5 have been investigated in various studies, highlighting its capability to elicit robust T-cell responses in cancer patients. Moreover, MAGEA5’s expression correlates with various malignancies, including melanoma, lung, and prostate cancers, indicating its role in tumor immunogenicity. By generating recombinant MAGEA5 proteins, researchers aim to study its structural and functional properties, contributing to the development of novel immunotherapeutic strategies. This includes the potential design of peptide-based vaccines and adoptive T-cell therapies that specifically target MAGEA5-expressing tumors. Overall, the study of MAGEA5 recombinant proteins holds promise for advancing our understanding of tumor-specific antigens and enhancing the effectiveness of cancer immunotherapies.
